All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Sub-analysis of East Asian patients from the ALCYONE trial

Feb 14, 2020
Share:

ALCYONE (NCT02195479) is a randomized, open-label, phase III trial of daratumumab in combination with bortezomib, melphalan, and prednisone (D-VMP) vs bortezomib, melphalan, and prednisone (VMP) alone in patients with newly diagnosed multiple myeloma (NDMM) ineligible for autologous stem cell transplantation (auto-SCT).

The Multiple Myeloma (MM) Hub previously covered the overall survival analysis from the ALCYONE trial that was presented at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition.1 Here, we present the results of a sub-analysis of East Asian patients.2

Patients and treatment2

  • A total of 91 East Asian patients enrolled in the ALCYONE clinical trial were included in this analysis (for details on the ALCYONE study design, click here):
    • Fifty Japanese patients: 24 in the D-VMP group and 26 in the VMP group
    • Forty-one Korean patients: 23 in the D-VMP group and 18 in the VMP group
  • Patient characteristics:
    • Median age: 71 years (range, 64–93)
    • High cytogenetic risk: D-VMP vs VMP, 9 (20%) patients vs 6 (14%), respectively
    • Median number of cycles received, D-VMP vs VMP, respectively:
      • For Japanese patients: 14 (1–21) vs 9 (1–9)
      • For Korean patients: 13 (1–20) vs 6 (1–9)
    • The clinical cut-off date for this analysis was June 12, 2017

Results2

Efficacy

After a median follow-up of 17.1 and 15.9 months for Japanese and Korean patients, respectively:

  • The median progression-free survival (PFS) in the D-VMP group vs the VMP group, respectively, was:
    • Japanese patients: not reached (NR) vs7 months (HR 0.29; 95% CI, 0.07–1.12)
    • Korean patients: NR vs0 months (HR 0.19; 95% CI, 0.06–0.64)
  • The 18-month PFS rate for D-VMP vs VMP, respectively, was:
    • Japanese patients: 84% (95% CI, 55–95) vs 64% (95% CI, 35–82)
    • Korean patients: 81% (95% CI, 56–92) vs 25% (95% CI, 4–54)
  • The best overall responses and the measurable residual disease (MRD)-negative rates (at a 10−5 sensitivity threshold) are reported in Table 1
  • No patients had progressive disease

Table 1. Overall best responses and MRD-negative rates

CI, confidence interval; CR, complete response; D-VMP, daratumumab + bortezomib + melphalan + prednisone; MRD, measurable residual disease; NE, not estimable; ORR, overall response rate; PR, partial response; sCR, stringent complete response; SD, stable disease; VGPR, very good partial response; VMP, bortezomib + melphalan + prednisone

 

 

Outcome measure

Japanese

Korean

D-VMP

n = 24

VMP

n = 26

D-VMP

n = 23

VMP

n = 18

ORR, %

sCR

CR

VGPR

PR

95.8

50.0

4.2

25.0

16.7

92.3

19.2

3.8

38.5

30.8

91.3

17.4

26.1

39.1

8.7

61.1

5.6

11.1

22.2

22.2

SD, %

4.2

7.7

4.3

27.8

CR or better, %

54.2

23.1

43.5

16.7

VGPR or better, %

79.2

61.5

82.6

38.9

Median time to best response, months

(range)

8.1

(0.8–15.7)

3.5

(0.8–14.4)

4.8

(0.7–14.4)

3.6

(1.4–13.0)

Median duration of response, months

(95% CI)

NE

19.9

NE

13.9

(14.4–19.9)

(9.6–NE)

MRD-negative rate, %

33

8

17

0

Safety

  • The incidence of cytopenias was higher in the Japanese group than in the global ALCYONE safety population (Tables 2, 3)
  • The most common non-hematologic Grade 3/4 treatment-emergent adverse event (TEAE) was pneumonia (given as D-VMP vs VMP):
    • Japanese patients: 8.3% vs 0
    • Korean patients: 17.4% vs 0 

Table 2. Most common (˃20%) hematologic TEAEs

D-VMP, daratumumab + bortezomib + melphalan + prednisone; TEAE, treatment-emergent adverse event; VMP, bortezomib + melphalan + prednisone

 

 

 

TEAE

ALCYONE safety population

Japanese

Korean

D-VMP

n = 346

VMP

n = 354

D-VMP

n = 24

VMP

n = 26

D-VMP

n = 23

VMP

n = 18

Thrombocytopenia, %

48.8

53.7

75.0

61.5

56.5

50.0

Neutropenia, %

49.7

52.5

62.5

61.5

52.2

38.9

Leukopenia, %

13.3

15.0

70.8

50.0

0

5.6

Lymphopenia, %

10.7

10.2

62.5

38.5

0

0

Anemia, %

28.0

37.6

16.7

26.9

30.4

38.9

Table 3. Most common (˃10%) hematologic Grade 3/4 (TEAEs)

D-VMP, daratumumab + bortezomib + melphalan + prednisone; TEAE, treatment-emergent adverse event; VMP, bortezomib + melphalan + prednisone

 

 

 

TEAE

ALCYONE safety population

Japanese

Korean

D-VMP

n = 346

VMP

n = 354

D-VMP

n = 24

VMP

n = 26

D-VMP

n = 23

VMP

n = 18

Thrombocytopenia, %

34.4

37.6

58.3

46.2

52.2

44.4

Neutropenia, %

39.9

38.7

58.3

61.5

52.2

38.9

Leukopenia, %

8.1

8.5

62.5

42.3

0

5.6

Lymphopenia, %

7.5

6.2

62.5

30.8

0

0

Anemia, %

15.9

19.8

8.3

23.1

26.1

27.8

Conclusions2

  • The efficacy results reported for East Asian patients are consistent with those from the global population of the ALCYONE study, with improvements in ORR and MRD-negativity rates for D-VMP vs VMP
  • Even though a higher rate of cytopenias was reported in Japanese patients compared to the ALCYONE population, these appear to have been well-managed and no patients discontinued treatment due to cytopenias
  • Although patient sample sizes were small, D-VMP treatment in East Asian patients was efficacious with no new safety signals, and the benefit of D-VMP was consistent with that of the global ALCYONE
  1. Mateos M.V. et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020 Jan 11; 395(10218):132–141. DOI: 10.1016/S0140-6736(19)32956-3
  2. Fujisaki T. et al. Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial. Ann Hematol. 2019 Dec; 98(12):2805–2814. DOI: 10.1007/s00277-019-03794-9
Share: